9月1日，和铂医药-B（02142）股价盘中大涨5.16%，引发市场关注。这一涨幅与公司近期发布的亮眼业绩密切相关。
根据和铂医药最新发布的2025年中期业绩报告，公司上半年总收入达7.25亿元，净利润约5.23亿元，同比激增51倍。这一惊人的业绩增长主要得益于公司成功的商务拓展（BD）策略。报告期内，和铂医药新增4项BD交易，其中来自阿斯利康的首付款和里程碑付款等达1.75亿美元。值得注意的是，和铂医药目前累计合作已超过40项，潜在总金额逾百亿美元，被市场称为"BD之王"。
和铂医药的表现也反映了整个创新药行业的积极趋势。2025年上半年，多家创新药企业如百济神州、乐普生物等实现扭亏为盈，行业整体呈现盈利向好的趋势。此外，国家医保局近期发布的首版商保创新药目录，以及其他支持创新药发展的政策措施，都为行业带来了新的发展机遇。在这一背景下，和铂医药作为行业领先企业之一，其股价表现获得了投资者的青睐。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.